Health · Pharma & Biotech · 15 hrs ago
Study links GLP-1 drug use with more reported nail problems
Researchers compared 575 people taking GLP-1 medicines with 1,329 people who had obesity and/or type 2 diabetes but had never taken them.
Participants came from France, the United States, Brazil and Mexico.
Nail detachment was reported by 39% of medicine users and 9% of nonusers, while discoloration affected 46% and 17%, respectively.
Overall, 66% of users reported at least one nail problem, compared with 53% of nonusers.
The researchers found that weight loss alone did not explain the differences, although existing skin conditions and nutritional deficiencies reduced some gaps.
The study shows an association, not that the medicines caused nail problems; about half of users said they had nail problems before treatment.
The findings were presented at the 2026 European Academy of Dermatology and Venereology Congress, and the researchers said more investigation is needed.
A multinational study found that people taking GLP-1 medications reported more nail problems than people who had never used the drugs.
Nail detachment was reported by 39% of GLP-1 users and 9% of nonusers.
Overall, 66% of users reported at least one nail disorder, compared with 53% of the control group.
Researchers said weight loss did not fully account for the differences, but the findings do not prove the medications cause nail problems.
The findings were presented at the European Academy of Dermatology and Venereology Congress 2026.
- Who
- Researchers studied 575 people using GLP-1 medications and 1,329 nonusers with type 2 diabetes and/or obesity.
- What
- The study found more reported nail problems among GLP-1 users, including nail detachment and discoloration.
- When
- The findings were presented at the European Academy of Dermatology and Venereology Congress 2026.
- Where
- Participants were recruited from France, the United States, Brazil, and Mexico.
- Why
- Researchers investigated possible links between GLP-1 medications and nail health; the reason for the reported differences is not established.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- GLP-1 users studied
- 575
- Nonusers in control group
- 1,329
- Nail detachment
- 39% of users; 9% of nonusers
- At least one nail disorder
- 66% of users; 53% of the control group
- Nail discoloration
- 46% of users; 17% of nonusers
- Participant countries
- France, United States, Brazil, and Mexico
What people are saying
Our findings show a clear association, but they also underline an important point: not everything that happens during GLP-1 treatment is necessarily caused by the treatment itself.
Sources
Related news
Bimatoprost eye lens shows early promise for cataracts and glaucoma
Italian Registry Study Finds Avacopan Appeared Effective for AAV
Merck’s eye drug meets main study goal, but results are mixed
FDA approves Asahi Kasei’s herpes treatment
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Bristol Myers reports two Phase 3 trial successes
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
GLP-1 drugs may have a role in addiction care, but questions remain
Brazil suspends Peptistrong supplement and orders all batches recalled
